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Abstract
Background: Urothelial carcinomas originate from the epithelial cells of the inner lining of the
bladder and may appear as single or as multiple synchronous tumors. Patients with urothelial
carcinomas frequently show recurrences after treatment making follow-up necessary. The leading
hypothesis explaining the origin of meta- and synchronous tumors assumes a monoclonal origin.
However, the genetic relationship among consecutive tumors has been shown to be complex in as
much as the genetic evolution does not adhere to the chronological appearance of the
metachronous tumors. Consequently, genetically less evolved tumors may appear chronologically
later than genetically related but more evolved tumors.
Methods: Forty-nine meta- or synchronous urothelial tumors from 22 patients were analyzed
using expression profiling, conventional CGH, LOH, and mutation analyses.
Results: We show by CGH that partial chromosomal losses in the initial tumors may not be
present in the recurring tumors, by LOH that different haplotypes may be lost and that detected
regions of LOH may be smaller in recurring tumors, and that mutations present in the initial tumor
may not be present in the recurring ones. In contrast we show that despite apparent genomic
differences, the recurrent and multiple bladder tumors from the same patients display remarkably
similar expression profiles.
Conclusion: Our findings show that even though the vast majority of the analyzed meta- and
synchronous tumors from the same patients are not likely to have originated directly from the
preceding tumor they still show remarkably similar expressions profiles. The presented data
suggests that an expression profile is established early in tumor development and that this profile
is stable and maintained in recurring tumors.
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Background
Urothelial carcinomas (UC) originate from the epithelial
cells of the inner lining of the bladder wall. The majority
is papillary and confined to the urothelial mucosa (stage
Ta) or to the lamina propria (stage T1) whereas the
remaining invades the underlying muscle tissue (T2),
perivesical fat (T3) or surrounding organs (T4). Most Ta
tumors are of low or medium grade (G1 or G2), rarely
progress, and are associated with a favorable prognosis
whereas high grade Ta (TaG3) and T1 tumors represent a
significant risk of tumor progression. UCs are character-
ized by a number of chromosomal and genetic alterations
of which cytogenetic loss and loss of heterozygosity
(LOH) of chromosome 9 is particularly frequent occur-
ring in > 50% of the cases [1-3]. Furthermore, activating
point mutations in the FGFR3 gene are found in > 70% of
Ta tumors, but rarely in invasive tumors [4]. A reverse pat-
tern is seen for TP53, which has led to the suggestion that
UC may develop through two different genetic pathways
[5]. Ta and T1 tumors are mostly treated by transurethral
resection, in many cases combined with subsequent intra-
vesical chemo- or immunotherapy. However, up to 70%
of the patients have local recurrences after treatment,
making follow-up by regular cytoscopy necessary. Further-
more, patients often show multiple synchronous tumors,
as well as concomitant hyperplasia, dysplasia, or cancer in
situ. Several investigations have shown that the majority,
if not all, meta- and synchronous tumors are clonally
related [6-8]. The leading hypotheses regarding the origin
of meta- and synchronous UC include intraepithelial
migration of tumor cells and intraluminal seeding from a
primary carcinoma [9]. Even though these models has
achieved some attention, they are at odds with the finding
that genomic relationships among consecutive tumors are
complex and do not adhere to a simple clonal evolution
[10]. In contrast, tumors from the same patient have been
shown to demonstrate similar expression profiles [11,12]
indicating a similarity at the transcriptional level not seen
at the genomic level. In the present investigation we
address this apparent contradiction by performing exten-
sive genomic and expressional profiling of several syn-
and metachronous bladder cancers.
Methods
Patients and Tissues
Urothelial tumors were collected by cold-cup biopsies
from the exophytic part of the bladder tumor in patients
undergoing transurethral resection at the University Hos-
pital of Lund, Sweden, between 2001 and 2005. The first
resected tumor is referred to as the initial (I) tumor and
the subsequent tumors as recurrences (R). The time
between initial and recurring tumors ranged between 4
and 31 months. Samples were immediately transferred
into transport media, transported to the laboratory and
frozen at -80°C. Tumor pathology and quality (> 70%
tumor cells) of tumor specimens was reviewed by one
pathologist (GC). Tumor progression in stage or grade
occurred in six and five patients, respectively. Regression
in stage was not seen whereas a lower grade was observed
in recurrent tumors from four patients. Normal urothelial
tissue samples were obtained from patients in surgery for
non UC-related disorders. The investigation was per-
formed with informed consent and approved by the local
ethical committee.
Extraction of nucleic acids
Total RNA was extracted using Trizol reagent (Invitrogen,
Carlsbad, CA) and purified on Qiagen RNeasy columns
(Qiagen, Valencia, CA). RNA sample integrities were
assessed on an Agilent 2100 Bioanalyzer (Agilent technol-
ogies, Palo Alto, CA) and samples that showed RNA deg-
radation (RNA integrity number, RIN, less than 7) were
excluded from further analyses. Genomic DNA was
extracted using the DNeasy Tissue kit (Qiagen) protocol.
Microarray hybridization and Data processing
In the present study, data from two different microarray
platforms was used. Data set 1 (Ta to T1 tumors hybrid-
ized to 25 k cDNA arrays) included 15 metachronous
tumors from 7 patients, tumors from 84 additional
patients and 8 normal samples. Microarray hybridization
and data pre- and postprocessing of tumors in Data set 1
was carried out as previously described [13]. Data set 2
(T1 to T4 tumors hybridized to 36 k oligonucleotide
arrays) comprised 38 meta- or synchronous tumors from
17 patients, 91 unique tumors, and 7 normal samples.
Samples in Data set 2 were hybridized to 36 k oligonucle-
otide arrays as described in Heidenblad et al. [14] In short,
postprocessing of data in Data set 2 was performed within
the Bioarray Software Environment (BASE) [15]. Spots of
poor quality identified through the image analysis were
removed followed by adjustment of the background cor-
rected Cy3 and Cy5 intensities by a pin-based lowess-fit
normalization algorithm. The dataset was further filtered
to remove spots with median ratio values for the Cy3 or
Cy5 channels lower than 15 counts. Replicate spots were
averaged and features with more than 20% missing values
were subsequently removed. Missing values were thereaf-
ter filled in using KNN imputation (k = 10). HCA and sta-
tistical analyses were performed using Statistica software
(StatSoft, Tulsa, OK). For HCA, 1-Pearson correlation was
used as distance measure and Wards' algorithm for cluster
formation.
Mutation, CGH, and LOH analyses
Mutation analyses were carried out by direct sequencing
of exons 7, 10, 13, and 15 for FGFR3 and exons 4 to 9 for
the TP53 gene. For samples in Data set 1, sequencing was
performed on cDNA transcribed from amplified RNA as
previously described [13]. For samples in Data set 2,BMC Cancer 2008, 8:183 http://www.biomedcentral.com/1471-2407/8/183
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sequencing was performed on genomic DNA using
BigDye terminator chemistry (Applied Biosystems, Foster
City, CA) and an ABI3700 automatic sequencer (Applied
biosystems), and analyzed using the SeqScape v2.5 soft-
ware (Applied Biosystems). All identified mutations were
verified by reverse sequencing on an independently gener-
ated amplicon. LOH analysis for seventeen highly poly-
morphic microsatellite markers distributed over both
arms of chromosome 9 was carried out on 36 tumors from
16 patients from which matching blood samples were
available as described in Lindgren et al. [13]. Genomic
profiles were obtained by conventional CGH for 35
tumors from 17 patients and performed as described by
El-Rifai et al. [16]
Results
Mutation, CGH, and LOH analyses
We selected 49 meta- or synchronous tumors from 22
patients for molecular analyses (Table 1). Tumors from
seven patients showed FGFR3 mutations (Table 1). In six
of these, both the initial and the recurring tumors showed
the same mutation. One patient (patient 43) showed dif-
ferent mutations in the initial and recurrent tumor. TP53
mutations were present in tumors from seven patients. In
two patients, the recurring tumor showed a mutation that
was not present in the initial tumor, and one patient
(patient 31) showed a mutation in the initial tumor that
was not seen in any of the three subsequent tumors. In the
two synchronous tumors from patient 56, only one had a
TP53 mutation. Hence, both FGFR3 and TP53 mutations
may occur independently in meta- and synchronous
tumors.
Genomic profiles were obtained by comparative genomic
hybridization (CGH) for 35 tumors from 17 patients
(Table 1). Taken together, the CGH analysis indicated
absence of clonal relationship in only two patients
(patients 38 and 54, respectively). However, patient 38
displayed the same point mutation in TP53 in both sam-
ples examined, strongly suggesting a clonal relationship.
Even though the vast majority of patients revealed a clonal
relationship between recurring tumors, different genomic
alterations were frequently observed in tumors from the
same patients. In particular, nine patients (53%) showed
genomic imbalance patterns in the recurrent tumors not
compatible with a simple karyotypic evolution from the
initial tumor (Table 1). For example, in patient 9 the ini-
tial tumor harbored partial losses of chromosome arms
2q, 6q, 10q, and 11p, which were not seen in the recurrent
tumor. Likewise in patient 13, the initial tumor harbored
partial losses of chromosomes 10 and 16, not seen in the
recurring tumors. In addition, 8 cases (47%) showed a
lower number of imbalances in the recurring than in the
initial tumor.
LOH analyses of 17 loci on chromosome 9 were per-
formed on 36 tumors from 16 patients (Figure 1). As for
the CGH analysis, the LOH patterns also pointed to a
complex genomic relationship between initial and recur-
ring tumors not compatible with a simple genetic progres-
sion model. For example, CGH data for patient 10
indicated 9q losses in both tumors whereas the LOH anal-
ysis showed loss of different haplotypes in the initial and
the recurring tumor, thereby indicating that different
chromosome homologues had been lost. The synchro-
nous tumors from patient 54 both showed LOH in the
CDKN2A-region on 9p. However, the regions showing
LOH are most likely caused by independent events as dif-
ferent D9S1679 alleles were lost in the synchronous S1
and S2 tumors, respectively. The initial and recurrent
tumor from patient 43 both showed LOH on 9q. How-
ever, the region of allelic imbalance was larger in the ini-
tial than in the recurring tumor and different alleles were
lost in the overlapping region at the D9S1781 and D9S154
loci. In this case, it is likely that mitotic recombination
occurred in a progenitor cell prior to the genomic events
leading to LOH. Altogether, the CGH and LOH analyses
show that no simple karyotypic relationship seem to exist
between initial and recurring or between synchronous
bladder tumors.
Gene expression profiling
Gene expression profiling of tumors from seven of the
patients was performed on a 25 k cDNA array. Expression
profiles of 8 normal samples and 85 additional patients
from which only one tumor sample was available (herein
referred as unique tumors) were used as reference samples
in a subsequently performed hierarchical cluster analysis
(HCA). The HCA revealed a remarkable similarity
between initial and recurrent tumors; samples from the
same patient clustered adjacent to each other in all cases
(Figure 2A). For the remaining 15 patients, tumor gene
expression profiles were obtained using a 36 k oligonucle-
otide array, and these were combined with profiles from
91 unique tumors and 9 normal samples. Again, a high
similarity in expression between samples from the same
patients was observed (Figure 2B). Two major exceptions
were however seen; initial and recurrent tumors from
patients 18 and 38 clustered separately in the two main
branches of the HCA dendogram. Notably, the shift in
HCA branch was linked to a progression from T1 to T2
tumors in both patients. Tumors from patients 16, 34, and
54 also showed variability among the expression profiles,
but to a lesser extent. In case of 34.I and 34.R1 this was
associated with progression to muscle-invasive growth.
Interestingly, in the tumors from patient 38 a large differ-
ence in gene expression was seen at the shift from stage T1
to T2, but the two subsequent T2 recurrences still clus-
tered adjacent to each other in the HCA dendogram.
Taken together, tumors from 18 out of 22 patients (82%)BMC Cancer 2008, 8:183 http://www.biomedcentral.com/1471-2407/8/183
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Table 1: Individual tumor characteristics, mutation, and CGH analyses
Tumor1 mtr2 Stage/grade3 FGFR3mut4,5 TP53mut4 Imbalances6
01.I TaG2 dim (8p., 22p, 22q11–13.1)
enh (8q11–q22, Xq)
01.R1 5 TaG2 dim (8p)
enh (8q)
02.I T2G3 dim (19p)
enh (1p31–p32, 1q23–q25, 8q, 12q13–q21)
02.R1 7 T2G3 enh (1q23–q24, 2p14-pter, 3p22-pter)
07.I TaG1 S249C na
07.R1 7 TaG2 S249C K132N na
09.I T1G3 G245D dim (2q33-qter, 6q24-qter, 9, 10q, 11p15-pter, 17, 22)
enh (1p11–p21, 1q11–q31, 2q11, 2q23–q24, 3, 8q11–q22, 11q14-qter, 16p, 16q11–
q13, 18p, 20, X)
09.R1 10 TIG3 G245D dim (9)
enh (1q22–q31, 2p13-pter, 3, 8, 16p, 16q11–q13, 20)
10.I T1G2 S249C R280T dim (9q)
enh (12q13–q21)
10.R1 5 T1G3 S249C R280T dim (9q22-qter, 10q24-qter)
enh (10q21–q23, 20q, Xp, Xq11–q24)
13.I T1G2 dim (9q, 10p12–p13, 16p, 17p, 19, 22)
enh (1p11–p31, 1q11–q41, 3, 5q14–q23, 8q13-qter, 12q15–q22, 13, 18q, 20p, X)
13.R1 6 T0 dim (4, 9, 17p, 19)
enh (1q23-qter, 3, 5q13–q23, 13, 14, 17q, 18q, 20, X)
14.I T1G2 dim (8p, 9, 10p, 17p)
enh (8q)
14.R1 8 T1G3 dim (9, 10p, 19)
enh (8q)
16.I TIG3 dim (8q)
enh (8p, 19)
16.R1 4 T1G2 dim (8q)
18.I T1G2 dim (8p)
enh (1p32-pter, 1p13–p21, 1q21–q31, 1q33–q35, 3, 5p, 6p11–p22, 8q21-qter, 10q11–
q23, 13q22-qter)
18.R1 16 T2G3 R273L enh (3, 8q11–q23, 9p)
21.I TaG2 dim (9q22-qter, 11p13-qter, 22)
enh (12p11–p12, 12q11–q23)
21.R1 7 T1G2 dim (8p, 9q, 10p, 11p, 11q11–q13.1, 12q24-qter, 16p, 17, 18p, 19, 22)BMC Cancer 2008, 8:183 http://www.biomedcentral.com/1471-2407/8/183
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enh (3, 4p11–p15, 4q11–q32, 5q21–q23, 6q11–q14, 8q, 12q15–q21, 13q14-qter, 
18q11–q22)
29.I TaG2 S249C dim (9q32-qter, 14q23-qter, 19)
enh (1q22-qter, 8q)
29.R1 21 TaG2 S249C dim (9q22-qter)
enh (1q11–q31, 13, X)
30.I TaG2 na
30.R1 13 TaG2 na
31.I TaG2 R290H na
31.R1 10 TaG2 na
31.R2 17 TaG2 dim (2q34-qter, 8p, 14, 19p)
enh (1q21-qter, 2p13-pter, 5p13-pter, 8q, 11q14–q24)
31.R3 19 T4G3 dim (2q31–q34, 5q11–q23, 6q, 9p12-pter)
enh (1q23–q24, 1q32-qter, 2p, 2q11–q14, 5p, 8)
34.I T1G3 S249C dim (9, 11p11-pter, 12p)
enh (1p31–p32, 1q23–q41)
34.R1 6 T2G3 S249C dim (8p, 9)
enh (8q)
38.I T1G3 R248Q dim (9)
38.R1 9 T2G3 R248Q na
38.R2 24 T2G3 R248Q dim (19p)
enh (2q14–q21, 8q22-qter)
42.I TaG2 S249C dim (5q, 10q11–q21, 10q23-qter, 13p, 13q11–q14, 15, 17p, 18q, 19p)
enh (2p13-pter, 3, 5p, 6p22-pter, 8q13-qter, 9p22.1-pter, 12q14–q21.2, 18p, X)
42.R1 31 TaG1 S249C enh (1q24-qter, 8q21–q23)
43.I TaG1 S249C na
43.R1 4 TaG1 Y375C na
47.I TaG2 na
47.R1 5 TaG2 na
47.R2 18 TaG1 na
53.I TaG2 S249C enh (X)
53.R1.S1 27 T1G2 S249C dim (19p)
53.R1.S2 27 T1G2 S249C dim (19p)
enh (Xp11-pter, Xq26-qter)
54.S1 - T1G3 enh (1q23)
Table 1: Individual tumor characteristics, mutation, and CGH analyses (Continued)BMC Cancer 2008, 8:183 http://www.biomedcentral.com/1471-2407/8/183
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54.S2 - T1G3 enh (8q21-qter, 12, 13)
56.S1 - T2G3 dim (2q32.2-qter, 5q, 15, 16q)
enh (1p, 1q12–q23, 3, 5p, 8q, 13q21-qter, 16p, 17q, 20, 21, Xp22-pter)
56.S2 - T2G3 Q331STOP dim (8p)
enh (1, 2p, 2q11–q21, 3, 5p, 6p12-pter, 6q21–q23, 7p, 7q32-qter, 8q, 10p, 15q21-
qter, 20)
64.S1 - T3G3 na na na
64.S2 - T3G3 na na na
1I, Initial tumor, i.e. the first resected tumor from a given patient; R, recurrent tumor; S, synchronous tumor.
2mtr, months to recurrence
3Histopathological staging and grading were reviewed according to the 2002 TNM and 1999 WHO classification systems by one single pathologist 
(GC)
4 Direct sequencing of exons 7, 10, and 15 of FGFR3 and exons 4 to 9 of TP53 was performed using BigDye terminator chemistry (Applied 
Biosystems, Foster City, CA). na, data not available either due no PCR products for sequencing or DNA quality unsuitable for CGH.
5FGFR3 amino acid positions are given according to the FGFR3 IIIb open reading frame; n/a, sequence data not available.
6Partial chromosomal losses in initial tumors incompatible with imbalances present in recurring tumors are in bold
Table 1: Individual tumor characteristics, mutation, and CGH analyses (Continued)
were grouped adjacent to, or in close vicinity of each
other, in the HCA.
To further investigate the similarity in gene expression
between tumors from the same patient, the 1-Pearson cor-
relation was calculated between the gene expression for
meta- or synchronous tumors from the same patient and
compared to the 1-Pearson correlations within the group
of normal and unique tumor samples, respectively (Figure
3A, and 3B). As most recurring tumors were either of stage
Ta or T1, only unique Ta and T1 tumors were considered
in this comparison. For the expression data obtained from
the cDNA-array, the median distances were 0.25 and 0.29
within the groups of unique Ta and T1 tumors, respec-
tively (Figure 3A). In contrast, metachronous tumors from
the same patient showed a much higher correlation
between samples, with a median distance of 0.09. The
mean distance among metachronous tumors from the
same patients was found to differ significantly from the
mean distances among unique Ta or T1 tumors (p < 0.001
LOH analyses of 36 tumors from 16 patients Figure 1
LOH analyses of 36 tumors from 16 patients. The markers are ordered according to their genomic position. The gap 
between markers indicates the location of the centromere.BMC Cancer 2008, 8:183 http://www.biomedcentral.com/1471-2407/8/183
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and p < 0.001, respectively, Mann-Whitney U-test), but
not from the distances between normal samples (p = 0.6).
Similar results were obtained when considering expres-
sion data obtained from the 36 k oligonucleotide plat-
form (Figure 3B). We did not consider metachronous
tumors showing progression from T1 to > T1 in this anal-
ysis. Again, the mean distances among tumors from the
same patient were significantly lower as compared to the
mean distance among unique tumors (p < 0.001), but not
from the mean distance among normal samples (p = 0.3).
For both the cDNA- and the oligonucleotide platforms,
the magnitude and variation of the distances among
recurrent and multiple tumors were the same as for dis-
tances among normal samples (Figure 3A and 3B), and
thus, the variability observed between meta- and synchro-
nous tumors from the same patient may largely be
explained by experimental variation, if assuming normal
samples from different individuals to be almost identical.
Furthermore, distances among synchronous tumors from
the same patients did not differ from distances among
metachronous tumors (p = 0.76). The observed similarity
is not likely to be caused by insufficient resection as the
majority of the recurrences show genomic alterations
incompatible with a simple re-growth from an initial
tumor. Hence, we argue that the highly similar gene
expression profiles observed for meta- and synchronous
tumors is a true biological feature of recurrent and multi-
ple tumors.
Discussion
The observed similarity at the expression level among syn-
and metachronous tumors revealed in the present investi-
gation, and noted by others [11,12], is in contrast to the
inconsistency seen at the genomic level. Even though
most recurring meta- and synchronous tumors showed a
clonal relationship, no simple genomic evolution from
chronologically early to late tumors could be invoked.
Partial chromosomal losses detected by CGH are highly
informative in this respect, as these events are not easily
compensated for by additional changes. Whole chromo-
some losses, on the other hand, may be counteracted by a
subsequent duplication of the remaining homolog and
Hierarchical cluster analysis (HCA) based on gene expression data Figure 2
Hierarchical cluster analysis (HCA) based on gene expression data. A) HCA of 15 metachronous tumors from 7 
patients, 84 unique tumors, and 8 normal samples hybridized to the 25k cDNA array. B) HCA of 38 meta- or synchronous 
tumors from 17 patients, 91 unique tumors, and 7 normal samples hybridized to the 36k oligonucleotide array. Meta- and syn-
chronous tumors from the same patients are colored the same.BMC Cancer 2008, 8:183 http://www.biomedcentral.com/1471-2407/8/183
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gains may be lost as a part of a genomic evolution. The ini-
tial tumors in 9 of the patients showed partial chromo-
some losses not seen in the recurring tumors. The LOH
analyses corroborated the complex genomic relationships
among related recurrences but also revealed further
incompatible genomic alterations not seen by CGH.
FGFR3 mutations are particularly frequent in low grade
and low stage tumors [4] and are believed to act as an
early genetic change in UC development. In spite of this,
one patient showed different FGFR3 mutations in the ini-
tial and the recurring tumor. The TP53 mutation pattern
was also incompatible with a simple genetic progression
model in 2 out of 7 patients. Clearly, meta- and synchro-
nous tumors show differences at the genomic level incom-
patible with a simple genetic progression from initial to
recurrent tumors.
The present findings further extend previously published
results showing that the chronology of tumor presenta-
tion is not reflected in the genetic progression of the
tumors [10]. These authors compared the chronology of
the genetic events with the chronology of tumor appear-
ance in patients with several recurrences and concluded
that the genetic progression trees, as determined by LOH
and mutation analyses, better reflected the tumor evolu-
tion than their chronologic order of presentation. Hence,
as also shown in the present investigation, tumors with
more evolved genomes may appear before clonally related
recurrences with less evolved genomes. This suggests that
pre-neoplastic cells with clonally related but differently
evolved genomes may co-exist in the urothelium, and that
cells in these fields may independently produce overt
tumors [17,18]. This suggestion is in agreement with sev-
eral histologic-genetic mapping investigations that have
shown that low grade intraurothelial lesions in patients
with UC share genomic and genetic changes with the adja-
cent tumors [19-23]. Notably, genomic imbalances and
gene mutations seen in synchronous tumors may also be
present in microscopically normal mucosa surrounding
the tumor foci, suggesting that synchronous tumors origi-
nate from fields of genetically altered urothelium. The
present findings further imply that the pre-neoplastic cells
maintained within the urothelium have acquired an
altered expression profile that is remarkably stable during
the subsequent genomic evolution leading to meta- and
synchronous Ta or T1 tumors. The formation of a fixed
expression profile is thus a likely primary event in the
development of UC.
Conclusion
Our findings show that meta- and synchronous tumors in
the bladder may harbor genomic alterations not compat-
ible with a simple tumor progression model. Even though
most alterations were clonal, recurring tumors are not
likely to have originated directly from the preceding
tumor. Compared with expression profiles for tumors in a
large reference set obtained from different patients, initial
and recurring tumors from the same patients showed
Box plots of 1-Pearson correlation distributions Figure 3
Box plots of 1-Pearson correlation distributions. A) 1-Pearson correlation distances among 8 normal samples, meta-
chronous samples from 7 patients, 62 unique Ta samples, and 19 unique T1 samples estimates from expression data obtained 
from the 25k cDNA platform. B) 1-Pearson correlation distances among 7 normal samples, meta- or synchronous tumors from 
12 patients, and 36 unique T1 tumors estimated from expression data obtained from 36k oligonucleotide platform. The calcu-
lation of distances among meta- and synchronous is based on distances among tumors originating from the same patients.BMC Cancer 2008, 8:183 http://www.biomedcentral.com/1471-2407/8/183
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remarkably similar expressions profiles; a similarity of the
same magnitude as among normal samples taken from
different individuals. The presented data suggests that an
expression profile is established early in tumor develop-
ment and that this profile is stable and maintained in
recurring tumors.
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